About US
Contact us
-
AstraZeneca creates unit to handle its COVID-19 vaccines, antibody treatmentsAs AstraZeneca suffered a series of missteps in the development, manufacture and distribution of its COVID-19 vaccine, other companies surged ahead in the race to provide shots to the world.2021/11/8
-
Johnson & Johnson scores reversal of landmark $465M opioid ruling in OklahomaFor years, Johnson & Johnson has been battling lawsuits alleging it played a role in creating the nationwide opioid epidemic. On Tuesday, just days after a high-profile trial win, the company sco2021/11/8
-
Johnson & Johnson, AbbVie, Teva and Endo score industry's first opioid trial winAs U.S. opioid litigation has evolved in recent years, drugmakers have watched the backlog of lawsuits grow as they've consistently failed to pick up any trial wins. This week in California, four com2021/11/3
-
Once sidelined, Eli Lilly's COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreementAfter a two-month hiatus, Eli Lilly’s COVID-19 antibody treatment is back in the game and hoping for a successful second chapter. On Tuesday, the companyrevealedthat it's has struck a dea2021/11/3
-
Incyte combats insurance hurdles for eczema cream Opzelura, but dermatologists fully on board: execIncyte’s Opzelura (ruxolitinib)cream to treat atopic dermatitis came to market with a classwide black box warning about potential side effects from JAK inhibitors.But to hear the company tell it, der2021/11/1
-
Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefitMerck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has withdrawn its notification of the Acceleron2021/11/1
-
Fujifilm starts build-out for massive NC plant, the latest piece of its multibillion-dollar CDMO expansion effortEarlier this month, when Fujifilm Diosynth broke ground in North Carolina on a facility destined to become its showcase, the occasion was more about the company than the plant. While the2021/10/27
-
Is Sandoz spinoff finally here? Novartis gets the ball rolling with strategic reviewWhen Novartis unveiled a plan in 2018 to grant its Sandoz generics business more autonomy, industry watchers read spinoff. Now, a separation may be around the corner. Novartis haslauncheda strateg2021/10/27
-
What would Medicare price negotiations bring to the US? Look to Europe, Lilly CEO Ricks saysWhen posed with the decades-old question of how drug price reform would affect theiroperations in the U.S., pharma execs have a ready-made response: Reducing drug prices would hinder innovation.2021/10/25
-
Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failureIs autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be no; but Novartis is still seeing2021/10/22